Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Approximately 3,300 subjects having completed IC51, JE-VAX or placebo treatment in studies IC51-301 or IC51-302 will take part in the safety follow up, up to month 6 after 1st vaccination in the study IC51-301 (NCT00604708) or IC51-302 (NCT00605085).
Only ~160 subjects, who have been treated with IC51 will take part in the immunogenicity and long-term analysis up to month 60.
Healthy subjects at least 18 years of age
Written informed consent obtained prior to study entry
Subjects correctly included and having completed clinical studies IC51-301 (NCT00604708) and IC51-302 (NCT00605085) with at least one vaccination
Inability or unwillingness to provide informed consent and to abide the requirements of the study
Central Nervous System Diseases
Nervous System Diseases
Central Nervous System Viral Diseases
RNA Virus Infections
Central Nervous System Infections
Physiological Effects of Drugs